Nelli Marina
The COVID-19 pandemic underscored the critical need for rapid, scalable, and effective vaccine production technologies. The unprecedented global effort to develop vaccines for SARS-CoV-2 led to significant advancements in viral antigen production, highlighting the capabilities of both prokaryote-based (bacterial) and eukaryote-based (cellular) expression systems. These systems are central to the production of viral antigens, which are crucial components of vaccines designed to induce an immune response. As the world moves beyond the pandemic, the demand for vaccines against emerging infectious diseases remains high, necessitating further improvements in the efficiency and versatility of these antigen production platforms.
PDFShare this article
Virology: Current Research received 187 citations as per Google Scholar report
